* Q1 revenue down 30 pct (All figures in U.S. dollars, unless noted)
TORONTO, March 16 (Reuters) - MDS Inc MDS.TO said on Tuesday it posted a first-quarter loss from continuing operations, due to falling revenue and restructuring charges.
The company posted a loss from continuing operations of $43 million, or 36 cents per share, compared with a year-ago profit of $3 million, or 3 cents a share.
The Toronto-based company has been selling its non-core operations to focus on its Nordion division — a supplier of medical isotopes for molecular imaging, radiotherapeutics and sterilization technologies.
Last month, it announced that Ricerca Biosciences would buy its pharma services business that provides clinical trial services to biotech and pharmaceutical companies. [ID:nN10150405]
In September, the company announced plans to sell its analytical tools division to U.S.-based Danaher Corp (DHR.N) for $650 million. [ID:nN02528673]
Quarterly revenue from continuing operations fell 30.3 percent to $46 million, as its Nordion business was hurt by the prolonged shutdown of Atomic Energy of Canada Limited’s (AECL) National Research Universal reactor. (Reporting by Euan Rocha, editing by Maureen Bavdek)